Last reviewed · How we verify
Vesicare
At a glance
| Generic name | Vesicare |
|---|---|
| Also known as | Vesicare (Solifenacin), Solifenacin, solifenacin, solifenacin succinate, YM905 |
| Sponsor | University of California, Irvine |
| Target | Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3 |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | discontinued |
Approved indications
- Bladder muscle dysfunction - overactive
- Increased Urinary Frequency
- Urge incontinence of urine
- Urgent desire to urinate
Common side effects
Key clinical trials
- Specified Drug Use Results Survey of Vesicare Tablets (N/A)
- A Prospective Randomized Controlled Trial: Comparison of the Transcutaneous Posterior Tibial Nerve Stimulation and Oral Solifenacin Treatments' Effects in Women Between 18-80 Years Old Who Have Overac (NA)
- Efficacy and Mechanism of High-Dose Vitamin D Supplementation in Pediatric OAB-Dry: A Randomized Clinical Trial Integrating Urinary Myelin Basic Protein as a Theranostic Biomarker (NA)
- Low-intensity Extracorporeal Shockwaves in the Treatment of Radiation Cystitis, Randomized Controlled Trial (EARLY/Phase 1)
- Electroacupuncture Versus Solifenacin Succinate for Female Overactive Bladder: A Multicenter, Randomized, Controlled, Noninferiority Trial (NA)
- A Phase 3, Double-Blind, Randomized, Multi-center, Placebo-Controlled Sequential Dose Titration Study to Assess Efficacy, Safety and Population Pharmacokinetics of Solifenacin Succinate Suspension in (Phase 3)
- Efficacy of Low-intensity Shock Wave Therapy on Persistent Storage Symptoms After Transurethral Surgery for Benign Prostatic Obstruction: A Randomized Controlled Trial (NA)
- Efficacy and Safety of Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vesicare CI brief — competitive landscape report
- Vesicare updates RSS · CI watch RSS
- University of California, Irvine portfolio CI